白细胞介素-6 (IL6) 是一种细胞因子，主要参与与各种疾病相关的炎症过程，从类风湿性关节炎和病原体引起的感染到癌症，其中恶性细胞表现出高度增殖和细胞因子（包括 IL6）的过度表达。此外，IL6 在检测和分化肿瘤细胞（包括结直肠癌 (CRC) 细胞）中发挥着重要作用。因此，鉴于其广泛的生物活性和病理作用，IL6 测定已被声称可用于免疫介导疾病的诊断/预后。在此，提出了标记和无标记电化学免疫传感器的比较研究，涉及用于检测 IL6 的分层 Au@Pt 纳米颗粒/聚合物混合材料。电化学免疫传感器独立耦合到先前用聚合物层修饰的丝网印刷碳电极（SPCE）的表面。在无标记免疫传感器中，抗 IL6 抗体 (IL6-Ab) 共价结合到修饰的 SPCE 表面，而在夹心式电流免疫传感器中，抗生物素化 IL6 抗体 (B-IL6-Ab) 与修饰的 SPCE 表面共价结合。通过生物素-亲和素亲和相互作用连接到电极。无标记格式采用微分脉冲伏安法 (DPV) 直接检测 IL6。由此产生的电化学免疫传感器表现出 50 至 750 pg/mL IL6 的线性动态范围，无标记免疫传感器和夹心式免疫传感器的检测限 (LOD) 分别为 14.4 和 6.0 pg/mL。这种出色的性能使它们成为对一组生物标志物进行临床分析的多功能平台，用于与肿瘤疾病及其他病理学相关的炎症过程的早期诊断/预后。© 2024。作者。

Interleukin-6 (IL6) is a cytokine mainly involved in inflammatory processes associated with various diseases, from rheumatoid arthritis and pathogen-caused infections to cancer, where malignant cells exhibit high proliferation and overexpression of cytokines, including IL6. Furthermore, IL6 plays a fundamental role in detecting and differentiating tumor cells, including colorectal cancer (CRC) cells. Therefore, given its range of biological activities and pathological role, IL6 determination has been claimed for the diagnosis/prognosis of immune-mediated diseases. Herein, a comparative study is presented of labeled and label-free electrochemical immunosensors involving a hierarchical Au@Pt nanoparticle/polymer hybrid material for detecting IL6. The electrochemical immunosensors were independently coupled to the surface of screen-printed carbon electrodes (SPCEs) previously modified with polymeric layers. While in the label-free immunosensor, an anti-IL6 antibody (IL6-Ab) was covalently bound to the modified SPCE surface, in the sandwich-like amperometric immunosensor, an anti-biotinylated-IL6 antibody (B-IL6-Ab) was attached to the electrode through biotin-avidin affinity interactions. The label-free format employed a straightforward detection of IL6 by differential pulse voltammetry (DPV). The resulting electrochemical immunosensors exhibited a linear dynamic range from 50 to 750 pg/mL IL6, with detection limits (LOD) of 14.4 and 6.0 pg/mL for label-free and sandwich-like immunosensors, respectively. This outstanding performance makes them versatile platforms for clinical analysis of a panel of biomarkers for early diagnosis/prognosis of inflammatory processes associated with oncological diseases, among other pathologies.© 2024. The Author(s).